Hims & Hers Health (NYSE:HIMS) CFO Oluyemi Okupe Sells 9,217 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 9,217 shares of the firm’s stock in a transaction that occurred on Friday, March 20th. The shares were sold at an average price of $23.77, for a total transaction of $219,088.09. Following the completion of the sale, the chief financial officer owned 318,789 shares in the company, valued at approximately $7,577,614.53. The trade was a 2.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Oluyemi Okupe also recently made the following trade(s):

• On Tuesday, January 20th, Oluyemi Okupe sold 9,067 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.34, for a total transaction of $275,092.78.
• On Monday, January 5th, Oluyemi Okupe sold 9,070 shares of Hims & Hers Health stock. The shares were sold at an average price of $33.79, for a total transaction of $306,475.30.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS opened at $21.39 on Wednesday. Hims & Hers Health, Inc. has a one year low of $13.74 and a one year high of $70.43. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70. The company has a market cap of $4.88 billion, a price-to-earnings ratio of 41.95, a PEG ratio of 2.60 and a beta of 2.55. The firm has a 50 day simple moving average of $22.39 and a 200 day simple moving average of $36.29.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, topping analysts’ consensus estimates of $0.02 by $0.06. The firm had revenue of $617.82 million for the quarter, compared to analysts’ expectations of $619.48 million. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The company’s revenue was up 28.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.11 earnings per share. Research analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Quent Capital LLC bought a new stake in shares of Hims & Hers Health in the 3rd quarter valued at about $28,000. Binnacle Investments Inc bought a new position in shares of Hims & Hers Health during the third quarter worth about $28,000. Virtus Advisers LLC acquired a new position in shares of Hims & Hers Health in the second quarter worth approximately $26,000. Hilltop National Bank acquired a new position in shares of Hims & Hers Health in the third quarter worth approximately $35,000. Finally, Skandinaviska Enskilda Banken AB publ boosted its holdings in Hims & Hers Health by 408.2% in the second quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company’s stock valued at $37,000 after acquiring an additional 600 shares during the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

HIMS has been the subject of a number of recent research reports. Morgan Stanley lowered their target price on Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating for the company in a report on Tuesday, February 24th. Barclays lifted their price target on Hims & Hers Health from $25.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, March 11th. Zacks Research raised Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. Evercore set a $24.00 price objective on shares of Hims & Hers Health in a report on Tuesday, February 24th. Finally, Bank of America upgraded shares of Hims & Hers Health from an “underperform” rating to a “neutral” rating and lifted their target price for the stock from $12.50 to $23.00 in a research report on Tuesday, March 10th. Three research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $31.29.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.